A study to investigate a new drug to treat Type 2 Diabetes

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-002931-25

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective of this study is to: • Determine the effect of ranolazine monotherapy on HbA1c in subjects with T2DM who are inadequately controlled with diet and exercise alone and who are treatment naïve to antihyperglycemic therapy or have not received antihyperglycemic therapy in the 90 days (or TZDs in the 24 weeks) prior to Screening


Critère d'inclusion

  • Type 2 diabetes mellitus